Stem definition | Drug id | CAS RN |
---|---|---|
human origin | 5500 | 1572943-04-4 |
Molecule | Description |
---|---|
Synonyms:
|
Tezepelumab-ekko is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody IgG2lambda that binds to human TSLP with a dissociation constant of 15.8 pM and blocks its interaction with the heterodimeric TSLP receptor. TSLP is a cytokine mainly derived from epithelial cells and occupies an upstream position in the asthma inflammatory cascade. Airway inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes, ILC2 cells) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) are involved in airway inflammation. Blocking TSLP with tezepelumab-ekko reduces biomarkers and cytokines associated with inflammation including blood eosinophils, airway submucosal eosinophils, IgE, FeNO, IL-5, and IL-13; however, the mechanism of tezepelumab-ekko action in asthma has not been definitively established.
|
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 19, 2022 | EMA | ASTRAZENECA AB | |
Dec. 17, 2021 | FDA | ASTRAZENECA AB | |
Sept. 26, 2022 | PMDA | ASTRAZENECA K.K |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Arthralgia | 54.52 | 41.58 | 50 | 766 | 569660 | 62918546 |
Anaphylactic reaction | 47.46 | 41.58 | 21 | 795 | 66079 | 63422127 |
None
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Arthralgia | 59.12 | 40.56 | 41 | 525 | 571762 | 79172060 |
None
Source | Code | Description |
---|---|---|
ATC | R03DX11 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES Other systemic drugs for obstructive airway diseases |
FDA EPC | N0000194010 | Thymic Stromal Lymphopoietin Blocker |
FDA MoA | N0000194011 | Thymic Stromal Lymphopoietin Blockers |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Severe asthma | indication | 370221004 |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Thymic stromal lymphopoietin | Cytokine | BLOCKER | 10.80 | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
CHEMBL3707229 | ChEMBL_ID |
C000622721 | MESH_SUPPLEMENTAL_RECORD_UI |
8933 | IUPHAR_LIGAND_ID |
DB15090 | DRUGBANK_ID |
018915 | NDDF |
4041094 | VANDF |
4041095 | VANDF |
D11771 | KEGG_DRUG |
C4550163 | UMLSCUI |
CHEMBL2109595 | ChEMBL_ID |
10172 | INN_ID |
2587789 | RXNORM |
354400 | MMSL |
40182 | MMSL |
d09841 | MMSL |
RJ1IW3B4QX | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
TEZSPIRE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-100 | INJECTION, SOLUTION | 210 mg | SUBCUTANEOUS | BLA | 28 sections |
TEZSPIRE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-100 | INJECTION, SOLUTION | 210 mg | SUBCUTANEOUS | BLA | 28 sections |
TEZSPIRE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-100 | INJECTION, SOLUTION | 210 mg | SUBCUTANEOUS | BLA | 28 sections |
TEZSPIRE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-112 | INJECTION, SOLUTION | 210 mg | SUBCUTANEOUS | BLA | 28 sections |
TEZSPIRE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-112 | INJECTION, SOLUTION | 210 mg | SUBCUTANEOUS | BLA | 28 sections |
TEZSPIRE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-112 | INJECTION, SOLUTION | 210 mg | SUBCUTANEOUS | BLA | 28 sections |
TEZSPIRE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55513-123 | INJECTION, SOLUTION | 210 mg | SUBCUTANEOUS | BLA | 28 sections |